Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

TGF-β induces PML SUMOylation, degradation and PML nuclear body disruption.

El-Asmi F, El-Mchichi B, Maroui MA, Dianoux L, Chelbi-Alix MK.

Cytokine. 2019 Aug;120:264-272. doi: 10.1016/j.cyto.2019.05.008. Epub 2019 May 29.

PMID:
31153006
2.

Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.

Vargas-Ayala RC, Jay A, Manara F, Maroui MA, Hernandez-Vargas H, Diederichs A, Robitaille A, Sirand C, Ceraolo MG, Romero-Medina MC, Cros MP, Cuenin C, Durand G, Le Calvez-Kelm F, Mundo L, Leoncini L, Manet E, Herceg Z, Gruffat H, Accardi R.

J Virol. 2019 Jun 14;93(13). pii: e00273-19. doi: 10.1128/JVI.00273-19. Print 2019 Jul 1.

PMID:
30996097
3.

Promyelocytic leukemia (PML) nuclear bodies (NBs) induce latent/quiescent HSV-1 genomes chromatinization through a PML NB/Histone H3.3/H3.3 Chaperone Axis.

Cohen C, Corpet A, Roubille S, Maroui MA, Poccardi N, Rousseau A, Kleijwegt C, Binda O, Texier P, Sawtell N, Labetoulle M, Lomonte P.

PLoS Pathog. 2018 Sep 20;14(9):e1007313. doi: 10.1371/journal.ppat.1007313. eCollection 2018 Sep.

4.

Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation.

Maroui MA, Maarifi G, McManus FP, Lamoliatte F, Thibault P, Chelbi-Alix MK.

Mol Cell Proteomics. 2018 Jun;17(6):1196-1208. doi: 10.1074/mcp.RA117.000447. Epub 2018 Mar 13.

5.

Differential effects of SUMO1 and SUMO3 on PKR activation and stability.

Maarifi G, El Asmi F, Maroui MA, Dianoux L, Chelbi-Alix MK.

Sci Rep. 2018 Jan 19;8(1):1277. doi: 10.1038/s41598-018-19683-6.

6.

Latency Entry of Herpes Simplex Virus 1 Is Determined by the Interaction of Its Genome with the Nuclear Environment.

Maroui MA, Callé A, Cohen C, Streichenberger N, Texier P, Takissian J, Rousseau A, Poccardi N, Welsch J, Corpet A, Schaeffer L, Labetoulle M, Lomonte P.

PLoS Pathog. 2016 Sep 12;12(9):e1005834. doi: 10.1371/journal.ppat.1005834. eCollection 2016 Sep.

7.

Small Ubiquitin-like Modifier Alters IFN Response.

Maarifi G, Maroui MA, Dutrieux J, Dianoux L, Nisole S, Chelbi-Alix MK.

J Immunol. 2015 Sep 1;195(5):2312-24. doi: 10.4049/jimmunol.1500035. Epub 2015 Jul 29.

8.

Large-scale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling.

Lamoliatte F, Caron D, Durette C, Mahrouche L, Maroui MA, Caron-Lizotte O, Bonneil E, Chelbi-Alix MK, Thibault P.

Nat Commun. 2014 Nov 13;5:5409. doi: 10.1038/ncomms6409.

PMID:
25391492
9.

Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells.

Zebboudj A, Maroui MA, Dutrieux J, Touil-Boukoffa C, Bourouba M, Chelbi-Alix MK, Nisole S.

Biochimie. 2014 Dec;107 Pt B:247-56. doi: 10.1016/j.biochi.2014.09.002. Epub 2014 Sep 21.

PMID:
25241256
10.

[Implication of PML nuclear bodies in intrinsic and innate immunity].

Maroui MA, El Asmi F, Dutrieux J, Chelbi-Alix MK, Nisole S.

Med Sci (Paris). 2014 Aug-Sep;30(8-9):765-71. doi: 10.1051/medsci/20143008014. Epub 2014 Sep 1. Review. French.

11.

Implication of PMLIV in both intrinsic and innate immunity.

El Asmi F, Maroui MA, Dutrieux J, Blondel D, Nisole S, Chelbi-Alix MK.

PLoS Pathog. 2014 Feb 27;10(2):e1003975. doi: 10.1371/journal.ppat.1003975. eCollection 2014 Feb.

12.

Differential Roles of PML Isoforms.

Nisole S, Maroui MA, Mascle XH, Aubry M, Chelbi-Alix MK.

Front Oncol. 2013 May 22;3:125. doi: 10.3389/fonc.2013.00125. eCollection 2013.

13.

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.

Maroui MA, Kheddache-Atmane S, El Asmi F, Dianoux L, Aubry M, Chelbi-Alix MK.

PLoS One. 2012;7(9):e44949. doi: 10.1371/journal.pone.0044949. Epub 2012 Sep 18.

14.

Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies.

Maroui MA, Pampin M, Chelbi-Alix MK.

J Virol. 2011 Dec;85(24):13164-73. doi: 10.1128/JVI.05808-11. Epub 2011 Oct 12.

15.

SUMOylation promotes PML degradation during encephalomyocarditis virus infection.

El McHichi B, Regad T, Maroui MA, Rodriguez MS, Aminev A, Gerbaud S, Escriou N, Dianoux L, Chelbi-Alix MK.

J Virol. 2010 Nov;84(22):11634-45. doi: 10.1128/JVI.01321-10. Epub 2010 Sep 8.

Supplemental Content

Loading ...
Support Center